There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NewAmsterdam Pharma Company (NAMS – Research Report) and Envista Holdings (NVST – Research Report) with bullish sentiments.
NewAmsterdam Pharma Company (NAMS)
Jefferies analyst Dennis Ding maintained a Buy rating on NewAmsterdam Pharma Company yesterday and set a price target of $24.00. The company’s shares closed last Thursday at $9.94, close to its 52-week low of $5.63.
According to TipRanks.com, Ding is ranked #7205 out of 8631 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for NewAmsterdam Pharma Company with a $25.00 average price target, implying a 156.4% upside from current levels. In a report issued on November 13, RBC Capital also maintained a Buy rating on the stock with a $25.00 price target.
See the top stocks recommended by analysts >>
Envista Holdings (NVST)
In a report released yesterday, Brandon Couillard from Jefferies maintained a Buy rating on Envista Holdings, with a price target of $32.00. The company’s shares closed last Thursday at $23.09, close to its 52-week low of $20.00.
According to TipRanks.com, Couillard is a top 100 analyst with an average return of
Currently, the analyst consensus on Envista Holdings is a Moderate Buy with an average price target of $28.86, a 23.8% upside from current levels. In a report issued on November 2, Stifel Nicolaus also maintained a Buy rating on the stock with a $30.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NAMS:
- NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
- AbbVie upgraded, Cisco downgraded: Wall Street’s top analyst calls
- NewAmsterdam Pharma initiated with an Outperform at RBC Capital
- NewAmsterdam announces appointment of Somaiya as CFO
- NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
